Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Judge Recommends Watson CEO Testify in FTC Probe

By Pharmaceutical Processing | August 20, 2010

NEW YORK (AP) — A federal judge has recommended Watson Pharmaceuticals CEO Paul Bisaro testify in a federal investigation into the generic drug developer’s patent settlement with biotechnology company Cephalon.

In a decision on Tuesday, Magistrate Alan Kay of U.S. District Court in Washington made the recommendation in the ongoing case. The Federal Trade commission has accused Watson of delaying an investigation into a potential “pay-for-delay” deal on a generic sleep disorder drug. It has subpoenaed Bisaro as part of the investigation into whether Cephalon paid off potential competitors to keep cheaper versions of its sleep disorder drug Provigil off the market.

The FTC is investigating whether Watson is purposely keeping a generic version of Provigil off the market as part of a deal with Cephalon. “Pay-for-delay” deals involve generic drug makers being offered patent dispute settlements in return for delaying launch of a generic version of a drug.

As part of the ongoing dispute, Watson has alleged that the FTC disclosed privileged information and urged the company to give up its exclusivity rights to a generic version of Provigil. The FTC has denied the allegations.

Watson has said it doesn’t comment on ongoing litigation.

“The facts before this court now do not establish a direct attempt by the FTC to misuse the court’s process, for it has not been show that the subpoena itself was issued to harass Mr. Bisaro or that the investigation has been conducted for an improper purpose,” Kay wrote in his decision.

Still, he disagreed with how the FTC conducted certain aspects of its investigation, particularly using its position to pressure the company into waiving statutory rights. Although the FTC’s approach was “questionable,” he said, it is not the court’s job to turn subpoena enforcement proceedings into “exhaustive inquisitions” of the FTC’s practices.

Watson and the FTC have 14 days to respond.

 

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards